ENROLLED
       2021 Legislature                           SB 530, 2nd Engrossed
       
       
       
       
       
       
                                                              2021530er
    1  
    2         An act relating to nonopioid alternatives; amending s.
    3         456.44, F.S.; authorizing certain health care
    4         practitioners to provide a specified educational
    5         pamphlet to patients in an electronic format;
    6         providing an effective date.
    7          
    8  Be It Enacted by the Legislature of the State of Florida:
    9  
   10         Section 1. Paragraph (c) of subsection (7) of section
   11  456.44, Florida Statutes, is amended to read:
   12         456.44 Controlled substance prescribing.—
   13         (7) NONOPIOID ALTERNATIVES.—
   14         (c) Except when a patient is receiving care in a hospital
   15  critical care unit or emergency department or a patient is
   16  receiving hospice services under s. 400.6095, before providing
   17  care requiring the administration of anesthesia involving the
   18  use of an opioid drug listed as a Schedule II controlled
   19  substance in s. 893.03 or 21 U.S.C. s. 812, or prescribing or
   20  ordering an opioid drug listed as a Schedule II controlled
   21  substance in s. 893.03 or 21 U.S.C. s. 812 for the treatment of
   22  pain, a health care practitioner who prescribes or orders an
   23  opioid drug must:
   24         1. Inform the patient or the patient’s representative of
   25  available nonopioid alternatives for the treatment of pain,
   26  which may include nonopioid medicinal drugs or drug products,
   27  interventional procedures or treatments, acupuncture,
   28  chiropractic treatments, massage therapy, physical therapy,
   29  occupational therapy, or any other appropriate therapy as
   30  determined by the health care practitioner.
   31         2. Discuss with the patient or the patient’s representative
   32  the advantages and disadvantages of the use of nonopioid
   33  alternatives, including whether the patient is at a high risk
   34  of, or has a history of, controlled substance abuse or misuse
   35  and the patient’s personal preferences.
   36         3. Provide the patient or the patient’s representative,
   37  electronically or in printed form, with a printed copy of the
   38  educational pamphlet described in paragraph (b).
   39         4. Document the nonopioid alternatives considered in the
   40  patient’s record.
   41         Section 2. This act shall take effect July 1, 2021.